U.S. pivotal clinical trial of Medtronic CoreValve begins

NewsGuard 100/100 Score

Medtronic, Inc. (NYSE: MDT) today announced the beginning of its Medtronic CoreValve® U.S. Pivotal clinical trial in the United States. The first CoreValve transcatheter aortic valve implantation (TAVI) procedure was performed by David H. Adams, M.D., and Samin K. Sharma, M.D., at The Mount Sinai Medical Center in New York City. The Medtronic CoreValve® System, a revolutionary treatment alternative to open-heart surgery for patients with severe aortic stenosis, will be investigated in more than 1,200 patients at up to 40 U.S. clinical trial sites. A second CoreValve case took place this week at El Camino Hospital in Mountain View, Calif.; St. Francis Hospital, The Heart Center in Roslyn, N.Y, also has been activated in the trial and is screening patients.

"Through this trial, we are investigating a minimally invasive, non-surgical alternative to open-heart surgery for valve replacement in patients with severe aortic stenosis," said Dr. Adams, who is chair of the Department of Cardiothoracic Surgery at Mount Sinai and is a national co-principal investigator of the CoreValve U.S. clinical trial. "This study will evaluate the safety and efficacy of the CoreValve system for use in the United States, where many thousands of patients are diagnosed with severe aortic stenosis every year."

The CoreValve System is designed with self-expandable technology to replace a diseased aortic valve percutaneously (through the skin), usually through the femoral artery, without open-heart surgery or surgical removal of the native valve. The CoreValve device is delivered through a controlled deployment delivery system.

"We are very excited with this first step in bringing this important transformational therapy to patients in the United States with life-threatening aortic valve disease, particularly those patients who have limited surgical options," said Jeffrey Popma, M.D., national co-principal investigator of the Medtronic CoreValve U.S. Pivotal Trial and director, Interventional Cardiology at the Beth Israel Deaconess Medical Center in Boston.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Pioneering vaccine strategy promises to outmaneuver antimicrobial resistance